Genetic Technologies Limited

GTG

AU000000GTG7

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 01:47:11 2024-04-26 am EDT			5-day change	1st Jan Change
0.12 ^AUD	+4.35%		-14.29%	-11.11%

Apr. 19	Genetic Technologies Raising $2 Million via ADS Offering	MT
Apr. 18	Top Midday Decliners	MT

Genetic Technologies Limited Announces Resignation of Nick Burrows as an Independent Non-Executive Director

February 15, 2024 at 08:00 am EST

Genetic Technologies Limited announced that as part of planned board renewal Nick Burrows has resigned as an Independent Non-Executive Director, effective February 15, 2024.

Latest news about Genetic Technologies Limited

Genetic Technologies Raising $2 Million via ADS Offering	Apr. 18	MT
Top Midday Decliners	Apr. 18	MT
Genetic Technologies Agrees to $2 Million Equity Offering	Apr. 18	MT
Genetic Technologies Limited Establishes Precision Oncology Division	Apr. 17	CI
Genetic Technologies Launches GeneType Precision Oncology Brand, Diagnostic Tests	Apr. 16	MT
Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston	Apr. 11	CI
Genetic Technologies to Conduct Breast Cancer Integration Study in US	Apr. 10	MT
Genetic Technologies Secures Short-Term Loan from Radium Capital	Mar. 25	MT
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Chief Financial Officer	Mar. 25	CI
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Company Secretary	Mar. 25	CI
Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare	Mar. 25	CI
Genetic Technologies Appoints CFO	Mar. 25	MT
Genetic Technologies Developing 'Most Advanced' Risk-Assessment Test for Serious Diseases; Shares Rise	Mar. 22	MT
Genetic Technologies to Work on Advanced Comprehensive Risk Test; Shares Jump 18%	Mar. 21	MT
Genetic Technologies to Launch US Advertising Campaign for Genome-Based Risk Assessment Test; Shares Surge 21%	Feb. 28	MT
Genetic Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 23	CI
Genetic Technologies Limited Announces Resignation of Nick Burrows as an Independent Non-Executive Director	Feb. 15	CI
Genetic Technologies Reports AU$3.6 Million in Q4 Cash Receipts	Jan. 31	MT
Genetic Technologies' CFO and Company Secretary Resigns; Shares Rise 3%	Jan. 07	MT
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer	Jan. 07	CI
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Company Secretary	Jan. 07	CI
Genetic Technologies Files $75 Million Mixed Shelf	Dec. 21	MT
Top Premarket Decliners	Dec. 18	MT
Genetic Technologies Secures Nearly AU$2 Million R&D Tax Rebate for Fiscal Year 2023	Dec. 18	MT
Transcript : Genetic Technologies Limited - Shareholder/Analyst Call	Nov. 21

Chart Genetic Technologies Limited

Duration

Period

More charts

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Sector

Healthcare Facilities & Services

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
GENETIC TECHNOLOGIES LIMITED	-11.11%	10.35M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B